June 27, 2022
Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.
June 26, 2022
LumiThera Inc. noted that the trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.
June 25, 2022
A team led by researchers from the University of Geneva has identified a molecular mechanism that causes degeneration of the eye’s photoreceptors, which can lead to blindness.
June 24, 2022
An end-of-week review of retina news and stories from June 18 to June 24.
June 23, 2022
Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
June 22, 2022
The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.
June 21, 2022
A study by Orbis International found that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.
June 20, 2022
A window into the world of academic retina practice today.
June 19, 2022
Study demonstrates results of pegcetacoplan as a geographic atrophy therapy.
June 18, 2022
Genetic and clinical research reveals new type of macular dystrophy, a cause of central vision loss.
